Palisade Bio, Inc., originally incorporated in Delaware in 2001 under the name Neuralstem, Inc., changed its name and completed the merger in 2021. The Company is a clinical-stage biopharmaceutical company focused on the development of next-generation once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases, and its lead drug candidate, PALI-2108, is being developed for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.
